Skip to Content

Tag: sulthiame


Also Noted

Apnimed sees Phase 2 positive results for sulthiame to treat OSA 

November 4, 2025HME News Staff

CAMBRIDGE, Mass. - Apnimed has announced The Lancet has published positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of obstructive sleep apnea (OSA). The study demonstrated that sulthiame significantly improved important OSA metrics in adults with moderate to severe OSA, the company says.  "The positive data from the FLOW trial confirm previous...

Apnimed, FLOW study, Obstructive Sleep Apnea (OSA), sulthiame


Read Full Articlered right arrow icon